Scheduling Nab-paclitaxel With Gemcitabine

Pancreatic Adenocarcinoma Metastatic Clinical Trial

— SIEGE  

Official title:

Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03529175
• Other study ID #: SIEGE (AX-PANC-PI-0101)
• Status: Completed
• Phase: Phase 2
• Start date: January 2014
• Est. completion date: June 2016

Study information

• Verified date: July 2019
• Source: Cambridge University Hospitals NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Metastatic pancreatic cancer is difficult to treat. Until recently, most patients would be offered treatment with a chemotherapy drug called gemcitabine. However, a large international trial showed that combining gemcitabine with a drug called nab-paclitaxel (or abraxane) was more effective compared with gemcitabine alone. The purpose of this study is to compare two different ways of combining gemcitabine with abraxane. Conventionally, both drugs are given on the same day via a drip into a vein in the arm but research suggests that giving abraxane 24 hours in advance of gemcitabine could possibly be more beneficial.

In this study, blood and tumour samples will be collected and analysed to try to confirm what has been seen in the laboratory studies. In addition, the investigators wish to find out whether certain tumour characteristics (called biomarkers) can be used to predict for response to chemotherapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 146
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged = 18 years old

• Signed informed consent and ability to comply with the protocol

• Histologically or cytologically confirmed metastatic PDAC

• Radiologically confirmed stage IV disease and measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; baseline tumour assessments and measurements must be done within 28 days prior to randomisation

• Karnofsky performance status =70%

• Life expectancy >12 weeks from the date of screening assessment

• Adequate bone marrow function

• Absolute neutrophil count (ANC) =1.5 x 109 /L

• Haemoglobin (Hb) = 100 g/L

• Platelets =100 x 109 /L

• White blood cell count (WBC) = 3 x 109 /L

• Adequate liver function

• Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =2.5 x upper limit of normal range (ULN)

• Total bilirubin <1.5 x ULN

• Adequate renal function defined as a serum creatinine =1.5 x ULN or calculated creatinine clearance by Cockcroft-Gault of =50 mL/min

• Received no prior systemic therapy for metastatic disease

• Prior adjuvant chemotherapy (with GEM or any other drug/s) is allowed if completed at least 6 months previously

• Prior radiotherapy is allowed as long as there is measurable disease which has not been irradiated

• Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, completion of QoL and HE questionnaires and other study procedures

• Confirmation of tumour tissue sample collected within 12 weeks prior to randomisation and blood to be taken prior to randomisation

• Women of child-bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if age =55 years or 12 months if age >55 years, must have a negative serum or urine pregnancy test within 14 days prior to randomisation

• All WCBP and all sexually active male patients must agree to use effective contraception methods throughout the study and for 30 days after the final dose of study drug for WCBP and for up to 6 months after treatment for male patients

Exclusion Criteria:

• Patients with operable or locally advanced PDAC

• Other invasive malignancies diagnosed within the last 5 years, except non-melanoma skin cancer and localized cured prostate cancer

• Significant acute or chronic medical or psychiatric condition, disease or laboratory abnormality which in the judgment of the investigator would place the patient at undue risk or interfere with the trial. Examples include, but are not limited to:

• Patients who have had a venous thromboembolic event who are not appropriately anticoagulated or have had a significant bleeding episode in the 3 weeks prior to randomisation

• Patients with symptoms of severe chronic obstructive airways disease or significant shortness of breath at rest AND have an FEV1<1.0 L within the last 6 months

• Patients with a history of interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, cystic fibrosis or bronchiectasis

• Patients with uncontrolled ischaemic heart or other cardiovascular event (myocardial infarction (MI), new angina, stroke transient ischaemic attack (TIA), or new congestive cardiac failure (CCF)) within the last 6 months

• Patients with stable but significant cardiovascular disease defined by heart failure (New York Heart Association Functional Classification (NYHF) III or IV, see Appendix 3) or frequent angina

• Presence of active infection

• Cirrhotic liver disease, known chronic active or acute hepatitis B, or hepatitis C

• Known allergy or hypersensitivity to GEM or ABX

• Women who are pregnant, plan to become pregnant or are lactating

• Routine use of any of the following will exclude patients:

• Oral anti-oxidant supplements: beta-carotene, selenium, lutein, zeaxanthin, lycopene, pycnogenol, fernblock, omega-3S, vitamin C, vitamin E, astaxanthin

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Adenocarcinoma Metastatic

Intervention

Drug:
• Abraxane (nab-paclitaxel)

• Gemcitabine

Locations

Country	Name	City	State
United Kingdom	Ysbyty Gwynedd	Bangor
United Kingdom	Belfast City Hospital	Belfast
United Kingdom	Queen Elizabeth Hospital	Birmingham
United Kingdom	Bristol Haematology & Oncology Centre	Bristol
United Kingdom	Cambridge University Hospitals NHS Foundation Trust	Cambridge	Cambridgeshire
United Kingdom	Velindre Cancer Centre	Cardiff
United Kingdom	Colchester Hospital	Colchester
United Kingdom	University Hospitals Coventry & Warwickshire	Coventry
United Kingdom	Edinburgh Cancer Research Centre	Edinburgh
United Kingdom	The Beatson Oncology Centre	Glasgow
United Kingdom	The Royal Surrey County Hospital	Guildford
United Kingdom	St James' Institute of Oncology	Leeds
United Kingdom	Leicester Royal Infirmary	Leicester
United Kingdom	Clatterbridge Cancer Centre	Liverpool
United Kingdom	Barts Health NHS Trust	London
United Kingdom	Hammersmith Hospital	London
United Kingdom	The Royal Free Hospital	London
United Kingdom	University College London Hospital	London
United Kingdom	The Christie Hospital	Manchester
United Kingdom	Churchill Hospital	Oxford
United Kingdom	Peterborough City Hospital	Peterborough	Cambridgeshire
United Kingdom	Weston Park Hospital	Sheffield
United Kingdom	Royal Cornwall Hospital	Truro

Sponsors (2)

Lead Sponsor	Collaborator
CCTU- Cancer Theme	Celgene

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival	The primary objective of the trial is to investigate the outcome of sequential administration of nab-paclitaxel combined with gemcitabine (ABX/GEM, 24 hours apart) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in terms of progression-free survival.	From participant randomisation to the point at which disease progression is reported (i.e. 12 months)
Secondary	Patient Safety	Adverse Events (including Serious Adverse Events), abnormal laboratory test results and performance status	1 year after end of treatment visit
Secondary	Treatment Efficacy	response to treatment assessed using radiological RECIST criteria	8 weeks

External Links

•   University of Cambridge Pancreatic Cancer Centre